Literature DB >> 17542512

Expression of O6-methylguanine-deoxyribose nucleic acid methyltransferase and temozolomide response in a patient with a malignant spinal cord astrocytoma. Case report.

Richard A Rovin1, Robert Winn.   

Abstract

The authors report the case of a 28-year-old woman with a high-grade spinal cord astrocytoma. Treatment using surgery, radiation, and temozolomide (TMZ) led to functional recovery and regression of the residual tumor as demonstrated on serial magnetic resonance images. Genetic testing revealed that this tumor did not express the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). This is the first report in the literature correlating MGMT expression with the clinical response of a high-grade spinal cord astrocytoma treated using TMZ.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542512     DOI: 10.3171/spi.2007.6.5.447

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  4 in total

1.  Temozolomide or bevacizumab for spinal cord high-grade gliomas.

Authors:  Thomas J Kaley; Ijah Mondesire-Crump; Igor T Gavrilovic
Journal:  J Neurooncol       Date:  2012-06-08       Impact factor: 4.130

Review 2.  Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.

Authors:  Wook Ha Kim; Wook-Ha Kim; Sang Hoon Yoon; Chae-Yong Kim; Ki-jeong Kim; Min Mi Lee; Gheeyoung Choe; In-Ah Kim; Jee Hyun Kim; Yu Jung Kim; Hyun-Jib Kim
Journal:  J Neurooncol       Date:  2010-06-05       Impact factor: 4.506

3.  A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma.

Authors:  Peng Sun; Duo-Jiao Fan; Tao Fan; Xin Li; Xue-Ling Qi; Xin-Gang Zhao; Qi-Fei Gai
Journal:  J Inflamm Res       Date:  2021-09-18

Review 4.  Surgical approaches to intramedullary spinal cord astrocytomas in the age of genomics.

Authors:  Andrew M Hersh; George I Jallo; Nir Shimony
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.